# Evaluation of SQ109, High-dose Rifampicin, and Moxifloxacin in Adults With Smear-positive Pulmonary TB in a MAMS Design

> **NCT01785186** · PHASE2 · COMPLETED · sponsor: **Michael Hoelscher** · enrollment: 365 (actual)

## Conditions studied

- Tuberculosis, Pulmonary

## Interventions

- **DRUG:** SQ109
- **DRUG:** Rifampicin
- **DRUG:** Moxifloxacin
- **DRUG:** isoniazid
- **DRUG:** pyrazinamide
- **DRUG:** ethambutol
- **DIETARY_SUPPLEMENT:** pyridoxine

## Key facts

- **NCT ID:** NCT01785186
- **Lead sponsor:** Michael Hoelscher
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04
- **Primary completion:** 2014-09
- **Final completion:** 2015-03
- **Target enrollment:** 365 (ACTUAL)
- **Last updated:** 2017-09-20

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01785186

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01785186, "Evaluation of SQ109, High-dose Rifampicin, and Moxifloxacin in Adults With Smear-positive Pulmonary TB in a MAMS Design". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01785186. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*